This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Nissen SE et al. (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291: 1071–1080
Cannon CP et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495–1504
Dornbrook-Lavender KA and Pieper JA (2003) Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy. Cardiovasc Drugs Ther 17: 75–82
Kajinami et al. (2004) Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 177: 219–234
Niemi M et al. (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14: 429–440
Kajinami K et al. (2004) CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 93: 104–107
Chasman DI et al. (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291: 2821–2827
Stengard JH et al. (2002) Contributions of 18 additional DNA sequence variations in the gene encoding apolipoprotein E to explaining variation in quantitative measures of lipid metabolism. Am J Hum Genet 71: 501–517
Weitz-Schmidt G et al. (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7: 687–692
Pharmacogenetics Network for Cardiovascular Risk Therapy [http://www.pharmgkb.org/network/members/parc.jsp]
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Supplementary Figure 1
Change in Total Cholesterol (p = 0.0011) The variation in cholesterol reduction with statin therapy in the PRINCE trial.6. Both panels show the distribution of total cholesterol lowering (mg/dl) dependent on the genotype of hmgcr polymorphism #12. (A) Left panel shows the median and interquartile range of cholesterol reduction for the subjects two genotypes observed in the study sample, AA and AT. (B) Right panel shows the mean and distribution of cholesterol reduction for study subjects with the two genotypes in white (AA) and gray (AT). TC, total cholesterol.
Rights and permissions
About this article
Cite this article
Chasman, D., Ridker, P. Pharmacogenetics: the outlook for genetic testing in statin therapy. Nat Rev Cardiol 2, 2–3 (2005). https://doi.org/10.1038/ncpcardio0071
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0071